OptiBiotix Health (OPTI)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 17.75p
   
  • Change Today:
      0.000p
  • 52 Week High: 39.00p
  • 52 Week Low: 6.00p
  • Currency: UK Pounds
  • Shares Issued: 97.94m
  • Volume: 1,875
  • Market Cap: £17.38m

OptiBiotix sees serious surge in sales in first half

By Josh White

Date: Monday 20 Jul 2020

LONDON (ShareCast) - (Sharecast News) - OptiBiotix Health said on Monday that invoiced sales of its 'LPLDL' and 'SlimBiome' products as ingredients or final products totalled £0.74m in the first half of its financial year, representing a 398% year-on-year increase.
The AIM-traded life sciences company noted the year-on-year increase in revenue growth from 7.7% in 2018, to 84.7% in 2019, to 398% now, came more agreements generated revenues and its partners grew sales from successful product launches.

The functional fibres division, led by Dr Fred Narbel, reported a profit during the period, while the ProBiotix division was profitable in three of the six months, and the consumer health division was profitable in one of the six months.

The company also received £0.75m of investment income in the period from the disposal of shares in SkinBioTherapeutics.

OptiBiotix signed 15 commercial agreements in the first half - 11 for SlimBiome, and four for LPLDL. The board said the deals opened retail opportunities in the UK, Australia, parts of Asia, the Middle East, and North America.

Sales of LPLDL as an ingredient or final product grew by 477% year-on-year, with the board noting the launch of AlfaSigma's 'Ezimega 3' product, and the commercial growth of Seed Health's 'Daily Synbiotic'.

Sales of SlimBiome as an ingredient or final product grew by 1,309% over the first half of last year, driven by partners in the UK, Australia and the US either launching retail products or building stock levels for the launch of products.

"There is now a trend showing an acceleration in year on year revenue growth as more agreements generate revenues, existing partners grow sales, and more retail partners launch products," said chief executive officer Stephen O'Hara.

"We anticipate further revenue growth in 2020 as interest in the microbiome and products for health and wellbeing grows."

At 0917 BST, shares in OptiBiotix Health were down 0.76% at 52.1p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

OPTI Market Data

Currency UK Pounds
Share Price 17.75p
Change Today 0.000p
% Change 0.00 %
52 Week High 39.00p
52 Week Low 6.00p
Volume 1,875
Shares Issued 97.94m
Market Cap £17.38m

OPTI Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
59.37% above the market average59.37% above the market average59.37% above the market average59.37% above the market average59.37% above the market average
92.45% above the sector average92.45% above the sector average92.45% above the sector average92.45% above the sector average92.45% above the sector average
Price Trend
22.02% below the market average22.02% below the market average22.02% below the market average22.02% below the market average22.02% below the market average
40.35% above the sector average40.35% above the sector average40.35% above the sector average40.35% above the sector average40.35% above the sector average
Income Not Available
Growth
96.45% below the market average96.45% below the market average96.45% below the market average96.45% below the market average96.45% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average

OPTI Dividends

No dividends found

Trades for 24-Apr-2024

Time Volume / Share Price
12:16 1,665 @ 17.50p
10:01 5 @ 18.00p
08:00 150 @ 18.00p
08:00 55 @ 18.00p

OPTI Key Personnel

CEO Stephen O'Hara
Finance Director Graham Myers

Top of Page